Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease melanoma, malignant
Symptom C0220650|brain metastases
Sentences 52
PubMedID- 25864098 Survival patterns following brain metastases for patients with melanoma in the map-kinase inhibitor era.
PubMedID- 22385786 Therapeutic braf inhibitors have shown clinically meaningful activity, particularly in metastatic braf v600e mutated melanoma including patients with brain metastases.
PubMedID- 22904648 However, retrospective subgroup analysis of 12 melanoma subjects with treated brain metastases who received ipilimumab showed that two achieved a partial response and an additional three had stable disease.36 median overall survival in this small group was 14 months and ranged to greater than 56 months.
PubMedID- 25164960 Historically, melanoma with brain metastases has a poor prognosis.
PubMedID- 23462208 Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.
PubMedID- 22084751 Gamma knife radiosurgery or surgical resection of cns disease prior to chemotherapy improves survival versus delayed treatment in patients melanoma with melanoma brain metastases 4.
PubMedID- 24403263 We analyzed the clinical and radiographic records of melanoma patients with brain metastases who were treated with whole brain radiation therapy or stereotactic radiosurgery between 2005 and 2012.
PubMedID- 24077406 Background: the development of brain metastases is common in patients with melanoma and is associated with a poor prognosis.
PubMedID- 21074062 Temozolomide and fotemustine are preferentially used in melanoma patients with brain metastases in the united states and in europe, respectively, with modest clinical activity.
PubMedID- 22906295 Complete skin, mucosal and retinal examination failed to show any primary lesion, therefore a diagnosis of primary cervical melanoma with brain metastases was made.
PubMedID- 25768829 Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without braf mutation and treatment.
PubMedID- 24954062 Background: brain metastases are common in patients with melanoma, and optimal management is not well defined.
PubMedID- 24455677 Therapies that affect the neoangiogenesis axis are not currently recommended in melanoma patients with brain metastases but data from ongoing trials are awaited with interest .
PubMedID- 23621583 In addition, the results of the phase ii study of dabrafenib in melanoma patients with active brain metastases (break-mb) and the phase i/ii study of dabrafenib/trametinib are examined.
PubMedID- 24926818 Economic burden of brain metastases among patients with metastatic melanoma in a usa managed care population.
PubMedID- 23579338 This retrospective study suggests that melanoma patients with brain metastases harboring braf mutation appear to be a distinct sub-group with a favorable response to vemurafenib and radiation therapy and acceptable morbidity.
PubMedID- 22287956 Only a few of them will get a benefit from their systemic treatment: survival of ajcc stage iv melanoma patients with visceral/brain metastases can be estimated to 6–9 months.
PubMedID- 26205399 Clinical trials in melanoma patients with brain metastases.
PubMedID- 21949607 The brain is a common site of melanoma metastasis, with brain metastases contributing to 20%–54% of all deaths.32 patients at increased risk for brain metastases include males, patients with head and neck mucosal melanomas, and lesions with metastases to ≥3 regional lymph nodes.33 these late-stage patients with brain metastasis generally have a poor prognosis, and treatment options are limited.
PubMedID- 23634283 brain metastases occur in 15% of patients with melanoma and are associated with a dismal prognosis.
PubMedID- 26511495 The multivariate analysis showed a lower rate of brain metastases in patients with acral lentiginous melanoma and melanoma of unknown primary site.
PubMedID- 21204754 Ipilimumab has also shown promising activity in melanoma patients with brain metastases, and patients with non-small cell lung cancer, renal cell cancer, and castrate-resistant prostate cancer.
PubMedID- 20960525 Prognostic factors for survival in melanoma patients with brain metastases.
PubMedID- 24112545 Whole brain helical tomotherapy with integrated boost for brain metastases in patients with malignant melanoma-a randomized trial.
PubMedID- 22453023 brain metastases occur commonly in patients with metastatic melanoma, are associated with a poor prognosis, and cause significant morbidity.
PubMedID- 23687494 Mixed response to ipilimumab in a melanoma patient with brain metastases: case report and review of the literature.
PubMedID- 24295639 Background & aim: brain metastases are frequent in patients with metastatic melanoma, indicating poor prognosis.
PubMedID- 25275060 Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery.
PubMedID- 25991583 Treatment patterns and outcomes in braf v600e-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
PubMedID- 22051508 melanoma patients with brain metastases are usually excluded from clinical trials because of their expected survival of approximately 5 months.
PubMedID- 24292400 Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the anatolian society of medical oncology.
PubMedID- 26225580 The uk eap cohort provides important insight into treating melanoma patients with brain metastases.
PubMedID- 23845462 The development of brain metastases is common in patients with metastatic melanoma and heralds a particularly poor prognosis.
PubMedID- 26500646 Several studies have also provided evidence of ipilimumab effectiveness in cases of melanoma with brain metastases (165, 166).
PubMedID- 22220282 It is therefore likely that improved survival can currently be achieved in at least a subset of melanoma patients with brain metastases.
PubMedID- 22094106 Background: brain metastases afflict approximately half of patients with metastatic melanoma (mm) and small cell lung cancer (sclc) and represent the direct cause of death in 60 to 70% of those affected.
PubMedID- 24377476 Background: brain metastases commonly occur in patients with metastatic melanoma and are associated with a poor prognosis.
PubMedID- 25859247 Nevertheless, the activity of ipilimumab in 72 melanoma patients with brain metastases was assayed in an open-label, phase ii trial (41).
PubMedID- 23788878 A number of clinical trials showed low efficacy of anti-cancer agents in melanoma patients with brain metastases.
PubMedID- 23271367 Though brain metastases, especially with lung cancer, melanoma and breast cancer, are becoming a common clinical problem, limited treatment options have existed , such as gamma knife radiosurgeries , stereotactic radiosurgery or irradiation , uvc irradiation and whole brain radiotherapy .
PubMedID- 23117880 Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma.
PubMedID- 20169105 Other clinical trials using continuous gm-csf administration in advanced prostate cancer or sustained g-csf in stage iv melanoma with brain metastases reported a much better survival than when approved therapies were used.
PubMedID- 23504304 Malignant melanoma with brain metastases remains a difficult disease to treat.
PubMedID- 23170278 Ipilimumab in a phase ii trial of melanoma patients with brain metastases.
PubMedID- 23051966 Background: brain metastases are common in patients with metastatic melanoma and median overall survival from their diagnosis is typically 17-22 weeks.
PubMedID- 22456429 Background: brain metastases commonly develop in patients with melanoma and are a frequent cause of death of patients with this disease.
PubMedID- 23108247 Recent findings: braf inhibitors and the immunomodulatory anticytotoxic t-lymphocyte-associated antigen 4 antibody ipilimumab have shown clinically meaningful activity in melanoma patients with brain metastases.
PubMedID- 24250878 Hemorrhagic brain metastases as a manifestation of metastatic malignant melanoma.
PubMedID- 22584956 Venous thromboembolism (vte) is a frequent complication in melanoma patients with brain metastases (bm).
PubMedID- 25057167 Background: both gamma-knife radiosurgery (gkrs) and braf inhibitors (braf-i) have been shown to be useful in melanoma patients with brain metastases (bms), thus suggesting that it could be interesting to combine their respective advantages.

Page: 1 2